Kyle L. Kolaja

5.3k total citations · 1 hit paper
70 papers, 3.6k citations indexed

About

Kyle L. Kolaja is a scholar working on Molecular Biology, Cancer Research and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Kyle L. Kolaja has authored 70 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 15 papers in Cancer Research and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Kyle L. Kolaja's work include Carcinogens and Genotoxicity Assessment (14 papers), Computational Drug Discovery Methods (10 papers) and 3D Printing in Biomedical Research (9 papers). Kyle L. Kolaja is often cited by papers focused on Carcinogens and Genotoxicity Assessment (14 papers), Computational Drug Discovery Methods (10 papers) and 3D Printing in Biomedical Research (9 papers). Kyle L. Kolaja collaborates with scholars based in United States, Switzerland and United Kingdom. Kyle L. Kolaja's co-authors include Thomas Force, Liang Guo, James E. Klaunig, Blake D. Anson, Timothy J. Kamp, Earl F. Walborg, S Bachowski, Mark R. Fielden, Rory Abrams and James A. Thomson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of the American College of Cardiology and Nature Reviews Drug Discovery.

In The Last Decade

Kyle L. Kolaja

69 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents

2011 585 citations Liang Guo, Kyle L. Kolaja et al. profile →

Peers

Countries citing papers authored by Kyle L. Kolaja

Since Specialization

Citations

This map shows the geographic impact of Kyle L. Kolaja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle L. Kolaja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle L. Kolaja more than expected).

Fields of papers citing papers by Kyle L. Kolaja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle L. Kolaja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle L. Kolaja. The network helps show where Kyle L. Kolaja may publish in the future.

Co-authorship network of co-authors of Kyle L. Kolaja

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle L. Kolaja. A scholar is included among the top collaborators of Kyle L. Kolaja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle L. Kolaja. Kyle L. Kolaja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product 2024 ·Journal of Pharmaceutical Sciences ·Johanna Mora, (unknown), Jennifer Hu, (unknown), Jochem Gokemeijer, Kyle L. Kolaja, (unknown), Vibha Jawa, Yue Hai, (unknown), Sofie Denies, (unknown), Chloé Ackaert	1
2	A functional three-dimensional microphysiological human model of myeloma bone disease 2020 ·Journal of Bone and Mineral Research ·(unknown), Kyle L. Kolaja, Jessica Cottrell	16
3	Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective 2020 ·Regulatory Toxicology and Pharmacology ·Vincent L. Reynolds, Paul Butler, (unknown), Laura Aschenbrenner, Derek Best, (unknown), Meredith E. Crosby, Laura Custer, Patricia A. Escobar, Kyle L. Kolaja, Jonathan G. Moggs, Dana Shuey, (unknown), Terry Van Vleet, (unknown), Timothy K. Hart	1
4	Refining the Human iPSC-Cardiomyocyte Arrhythmic Risk Assessment Model 2013 ·Toxicological Sciences ·Liang Guo, Luke Coyle, Rory Abrams, Raymond A. Kemper, (unknown), Kyle L. Kolaja	108
5	Cancer Genetics and the Cardiotoxicity of the Therapeutics 2013 ·Journal of the American College of Cardiology ·Hind Lal, Kyle L. Kolaja, Thomas Force	47
6	A High-Throughput Screen for Teratogens Using Human Pluripotent Stem Cells 2013 ·Toxicological Sciences ·Sei Kameoka, Joshua Babiarz, Kyle L. Kolaja, Eric Chiao	50
7	Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes 2011 ·Nature Reviews Drug Discovery ·Thomas Force, Kyle L. Kolaja	278
8	Determination of the Human Cardiomyocyte mRNA and miRNA Differentiation Network by Fine-Scale Profiling 2011 ·Stem Cells and Development ·Joshua Babiarz, (unknown), Sriram Sridhar, Palanikumar Ravindran, (unknown), Hans Bitter, Thomas Weiser, Eric Chiao, Ulrich Certa, Kyle L. Kolaja	80
9	HPLC–MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium 2011 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Cristina Guallar-Hoyas, Filippos Michopoulos, J. Gerry Kenna, Kyle L. Kolaja, Hans V. Westerhoff, P. Thomas, Ian D. Wilson	29
10	Modeling Bone Marrow Toxicity Using Kinase Structural Motifs and the Inhibition Profiles of Small Molecular Kinase Inhibitors 2010 ·Toxicological Sciences ·Andrew Olaharski, (unknown), Nina Gonzaludo, Rama K. Kondru, David Goldstein, Tanja S. Zabka, Henry J. Lin, Thomas P. Singer, Kyle L. Kolaja	9
11	GADD45α induction in the greenscreen HC indicator assay does not occur independently of cytotoxicity 2010 ·Environmental and Molecular Mutagenesis ·Andrew Olaharski, Silvio Albertini, Lutz Mueller, Andreas Zeller, (unknown), Elmar Gocke, Kyle L. Kolaja	2
12	Testicular gene expression profiling following 2-methoxyethanol and 2-ethoxyethanol exposure in male rats reveals abnormal expression of the actin binding protein cortactin in degenerating spermatocytes 2009 ·Toxicology Letters ·(unknown), Matthew N. Cooper, Lance O. Lollini, (unknown), John Allard, Kyle L. Kolaja, Stefan Platz, Sushmita Chanda	4
13	In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates 2009 ·Toxicology Letters ·Andrew Olaharski, Hirdesh Uppal, Matthew N. Cooper, Stefan Platz, Tanja S. Zabka, Kyle L. Kolaja	21
14	Inhibition of gap-junctional-intercellular communication in thyroid-follicular cells by propylthiouracil and low iodine diet 2000 ·Toxicology ·Kyle L. Kolaja, Jay S. Petrick, Curtis D. Klaassen	9
15	The role of oxidative stress in chemical carcinogenesis. 1998 ·Environmental Health Perspectives ·James E. Klaunig, Yawei Xu, Jeffrey S. Isenberg, S Bachowski, Kyle L. Kolaja, (unknown), D.E. Stevenson, Earl F. Walborg	429
16	Dose–Response Examination of UDP-Glucuronosyltransferase Inducers and Their Ability to Increase both TGF-β Expression and Thyroid Follicular Cell Apoptosis 1998 ·Toxicological Sciences ·Kyle L. Kolaja	22
17	Vitamin E Modulation of Hepatic Focal Lesion Growth in Mice1 1997 ·Toxicology and Applied Pharmacology ·Kyle L. Kolaja, James E. Klaunig	34
18	Subchronic Effects of Dieldrin and Phenobarbital on Hepatic DNA Synthesis in Mice and Rats 1996 ·Toxicological Sciences ·Kyle L. Kolaja, (unknown), (unknown), Earl F. Walborg, James E. Klaunig	5
19	Subchronic Effects of Dieldrin and Phenobarbital on Hepatic DNA Synthesis in Mice and Rats 1996 ·Fundamental and Applied Toxicology ·Kyle L. Kolaja	57
20	CANCER BIOLOGY: Reversibility of promoter induced hepatic focal lesion growth in mice 1996 ·Carcinogenesis ·Kyle L. Kolaja, Donald E. Stevenson, Earl F. Walborg, James E. Klaunig	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact